Bendroflumethiazide: Difference between revisions

	WikiDoc Resources for Bendroflumethiazide
Articles
Most recent articles on Bendroflumethiazide Most cited articles on Bendroflumethiazide Review articles on Bendroflumethiazide Articles on Bendroflumethiazide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bendroflumethiazide Images of Bendroflumethiazide Photos of Bendroflumethiazide Podcasts & MP3s on Bendroflumethiazide Videos on Bendroflumethiazide
Evidence Based Medicine
Cochrane Collaboration on Bendroflumethiazide Bandolier on Bendroflumethiazide TRIP on Bendroflumethiazide
Clinical Trials
Ongoing Trials on Bendroflumethiazide at Clinical Trials.gov Trial results on Bendroflumethiazide Clinical Trials on Bendroflumethiazide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bendroflumethiazide NICE Guidance on Bendroflumethiazide NHS PRODIGY Guidance FDA on Bendroflumethiazide CDC on Bendroflumethiazide
Books
Books on Bendroflumethiazide
News
Bendroflumethiazide in the news Be alerted to news on Bendroflumethiazide News trends on Bendroflumethiazide
Commentary
Blogs on Bendroflumethiazide
Definitions
Definitions of Bendroflumethiazide
Patient Resources / Community
Patient resources on Bendroflumethiazide Discussion groups on Bendroflumethiazide Patient Handouts on Bendroflumethiazide Directions to Hospitals Treating Bendroflumethiazide Risk calculators and risk factors for Bendroflumethiazide
Healthcare Provider Resources
Symptoms of Bendroflumethiazide Causes & Risk Factors for Bendroflumethiazide Diagnostic studies for Bendroflumethiazide Treatment of Bendroflumethiazide
Continuing Medical Education (CME)
CME Programs on Bendroflumethiazide
International
Bendroflumethiazide en Espanol Bendroflumethiazide en Francais
Business
Bendroflumethiazide in the Marketplace Patents on Bendroflumethiazide
Experimental / Informatics
List of terms related to Bendroflumethiazide

Bendroflumethiazide
Clinical data
AHFS/Drugs.com	Consumer Drug Information
Pregnancy; category	Risk neonatal thrombocytopenia in 3rd trimester;
Routes of; administration	Oral
ATC code	C03AA01 (WHO) ;
Legal status
Legal status	UK: POM (Prescription only) ;
Pharmacokinetic data
Bioavailability	100%
Protein binding	96%
Metabolism	extensive
Elimination half-life	3-4 hours
Identifiers
	IUPAC name 3-Benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide;
CAS Number	73-48-3 ;
PubChem CID	2315;
DrugBank	DB00436 ;
ChemSpider	2225 ;
UNII	5Q52X6ICJI;
KEGG	D00650 ;
ChEBI	CHEBI:3013 ;
ChEMBL	ChEMBL1684 ;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C15H14F3N3O4S2
Molar mass	421.415 g/mol
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)c3c(cc1c(NC(NS1(=O)=O)Cc2ccccc2)c3)S(=O)(=O)N;
	InChI InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23) ; Key:HDWIHXWEUNVBIY-UHFFFAOYSA-N ;
(verify)

← Older edit

VisualWikitext

Latest revision as of 03:21, 2 May 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bendroflumethiazide (INN), formerly bendrofluazide (BAN), trade name Aprinox, is a thiazide diuretic used to treat hypertension.

Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the distal convoluted tubule (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild heart failure although loop diuretics are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to vasodilation).

Common adverse effects:

postural hypotension
hyponatraemia, hypokalaemia, hypercalcaemia
gout
impaired glucose tolerance
impotence

Rare adverse effects:

References

↑ BNF 45 March 2003
↑ Ed. Sean C. Sweetman (ed.). Martindale: The complete drug reference (33 ed.). Pharmaceutical Press.

[1] BNF 45 March 2003

[2] Ed. Sean C. Sweetman (ed.). Martindale: The complete drug reference (33 ed.). Pharmaceutical Press.

[1]

[2]

@@ Line 1: / Line 1: @@
-__NOTOC__
+{{Drugbox
-{{drugbox
+| Watchedfields = changed
-| IUPAC_name = 3-benzyl-5,5-dioxo-9- (trifluoromethyl)-5λ<sup>6</sup>- thia-2,4-diazabicyclo[4.4.0]deca-7, 9,11-triene-8-sulfonamide
+| verifiedrevid = 459531641
-| image = Bendroflumethiazide-2D-skeletal.png
+| IUPAC_name = 3-Benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2''H''-1,2,4- benzothiadiazine-7-sulfonamide
 | image2 = Bendroflumethiazide-3D-vdW.png
+<!--Clinical data-->
+| tradename =
+| Drugs.com = {{drugs.com|CDI|bendroflumethiazide}}
+| pregnancy_AU =
+| pregnancy_US =
+| pregnancy_category = Risk neonatal [[thrombocytopenia]] in 3rd trimester<ref>[[British National Formulary|BNF]] '''45''' March 2003</ref>
+| legal_AU =
+| legal_CA =
+| legal_UK = POM
+| legal_US =
+| legal_status =
+| routes_of_administration = Oral
+<!--Pharmacokinetic data-->
+| bioavailability = 100%
+| protein_bound = 96%
+| metabolism = extensive
+| elimination_half-life = 3-4 hours<ref>{{cite book | editor = Ed. Sean C. Sweetman | title = [[Martindale: The complete drug reference]] | edition = 33 | publisher = Pharmaceutical Press}}</ref>
+<!--Identifiers-->
+| CASNo_Ref = {{cascite|correct|CAS}}
+| CAS_number_Ref = {{cascite|correct|??}}
 | CAS_number = 73-48-3
 | ATC_prefix = C03
 | ATC_suffix = AA01
 | ATC_supplemental =
 | PubChem = 2315
-| DrugBank = APRD00666
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
-| C=15 | H=14 | F=3 | N=3 | O=4 | S=2
+ | DrugBank = DB00436
-| molecular_weight = 421.417 g/mol
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
-| bioavailability = 100%
+| ChemSpiderID = 2225
-| protein_bound = 96%
+| UNII_Ref = {{fdacite|correct|FDA}}
-| metabolism = extensive
+| UNII = 5Q52X6ICJI
-| elimination_half-life = 3-4 hours<ref>{{cite book | editor=Ed. Sean C. Sweetman | title=[[Martindale: The complete drug reference]] | edition=33 | publisher=Pharmaceutical Press}}</ref>
+| KEGG_Ref = {{keggcite|correct|kegg}}
-| pregnancy_AU =
+| KEGG = D00650
-| pregnancy_US =
+| ChEBI_Ref = {{ebicite|correct|EBI}}
-| pregnancy_category = Risk neonatal [[thrombocytopenia]] in 3rd trimester<ref>[[British National Formulary|BNF]] '''45''' March 2003</ref>
+| ChEBI = 3013
-| legal_AU =
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
-| legal_CA =
+| ChEMBL = 1684
-| legal_UK = POM
-| legal_US =
+<!--Chemical data-->
-| legal_status =
+| C=15 | H=14 | F=3 | N=3 | O=4 | S=2
-| routes_of_administration = oral
+| molecular_weight = 421.415 g/mol
+| smiles = FC(F)(F)c3c(cc1c(NC(NS1(=O)=O)Cc2ccccc2)c3)S(=O)(=O)N
+| InChI = 1/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
+| InChIKey = HDWIHXWEUNVBIY-UHFFFAOYAU
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChI = 1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChIKey = HDWIHXWEUNVBIY-UHFFFAOYSA-N
 }}
+__NOTOC__
+{{SI}}
 {{CMG}}
+==Overview==
+'''Bendroflumethiazide''' ([[International Nonproprietary Name|INN]]), formerly '''bendrofluazide''' ([[British Approved Name|BAN]]), trade name '''Aprinox''', is a [[thiazide]] [[diuretic]] used to treat [[hypertension]].
+Bendroflumethiazide is a thiazide diuretic which works by inhibiting sodium reabsorption at the beginning of the [[distal convoluted tubule]] (DCT). Water is lost as a result of more sodium reaching the collecting ducts. Bendroflumethiazide has a role in the treatment of mild [[heart failure]] although [[loop diuretic]]s are better for reducing overload. The main use of bendroflumethiazide currently is in hypertension (part of the effect is due to [[vasodilation]]).
-'''Bendroflumethiazide''' [[International Nonproprietary Name|INN]] (formerly [[British Approved Name|BAN]] '''bendrofluazide'''), is a [[thiazide]] [[diuretic]], used to treat [[hypertension]].
+Common adverse effects:
-==Footnotes==
+* [[Orthostatic hypotension|postural hypotension]]
-<references/>
+* [[hyponatraemia]], [[hypokalaemia]], [[hypercalcaemia]]
+* [[gout]]
+* impaired glucose tolerance
+* [[impotence]]
+Rare adverse effects:
+* [[thrombocytopenia]]
+* [[agranulocytosis]]
+* [[pancreatitis]]
-{{Antihypertensives and diuretics}}
+==References==
+{{reflist|2}}
+[[Category:Drug]]
+[[Category:Carbonic anhydrase inhibitors]]
+[[Category:Organofluorides]]
 [[Category:Thiazides]]
-[[Category:Drugs]]
-{{WikiDoc Help Menu}}
-{{WikiDoc Sources}}

Clinical data

AHFS/Drugs.com	Consumer Drug Information
Pregnancy category	Risk neonatal thrombocytopenia in 3rd trimester^[1]
Routes of administration	Oral
ATC code	C03AA01 (WHO)
Legal status
Legal status	UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability	100%
Protein binding	96%
Metabolism	extensive
Elimination half-life	3-4 hours^[2]
Identifiers
IUPAC name 3-Benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1,2,4- benzothiadiazine-7-sulfonamide
CAS Number	73-48-3^Y
PubChem CID	2315
DrugBank	DB00436^Y
ChemSpider	2225^Y
UNII	5Q52X6ICJI
KEGG	D00650^Y
ChEBI	CHEBI:3013^Y
ChEMBL	ChEMBL1684^Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₁₅H₁₄F₃N₃O₄S₂
Molar mass	421.415 g/mol
3D model (JSmol)	Interactive image
SMILES FC(F)(F)c3c(cc1c(NC(NS1(=O)=O)Cc2ccccc2)c3)S(=O)(=O)N
InChI InChI=1S/C15H14F3N3O4S2/c16-15(17,18)10-7-11-13(8-12(10)26(19,22)23)27(24,25)21-14(20-11)6-9-4-2-1-3-5-9/h1-5,7-8,14,20-21H,6H2,(H2,19,22,23)^Y Key:HDWIHXWEUNVBIY-UHFFFAOYSA-N^Y
(verify)

Bendroflumethiazide: Difference between revisions

Latest revision as of 03:21, 2 May 2015

Overview

References

Navigation menu

Search